CanSino's inhaled Covid vaccine gets emergency use approval in China
The inhaled Covid-19 vaccine has been approved for emergency use as a booster by the country's drug regulator.
-
McMaster University researchers demonstrate an inhaled Covid-19 vaccine in Phase 1 human trials. (Jon Castell/CBC)
China's CanSino Biologics Inc. said on Sunday that the Covid-19 vaccine it recently developed has been approved for emergency use as a booster by the country's drug regulator, potentially benefiting its business.
"The approval will have a positive impact on the company's performance if the vaccine is subsequently purchased and used by relevant government agencies," CanSino said.
In a filing on Sunday, the company said that the National Medical Products Administration has given the green light to the inhaled version of CanSino's Covid-19 vaccine; however, it alerted that it will face intense competition from other vaccines in the country that have received government approval, too, or are in clinical trials.
Read: Azvudine, China's COVID-19 pill, has been delivered to various regions
Emergency use authorization was given to Livzon Pharmaceutical Group Inc's Covid-19 vaccine as a booster, Livzon said on Friday, one of two new products against the virus that China had cleared in more than a year.
CanSino also said additional administrative approvals are still needed, so it was still not sure when the vaccine would go to market, adding that sales would depend on the Covid-19 situation within China and abroad, as well as the country's vaccination rate.
After a recent increase in Covid-19 cases, China's infections rebounded, and the southern tech hub of Shenzhen imposed a weekend lockdown in most of the city's parts on Saturday, while a lockdown was imposed on the southwestern metropolis of Chengdu on Thursday.
Mainland China reported 1,848 new Covid-19 cases on September 3, including symptomatic and asymptomatic infections, in comparison to 1,988 new cases a day earlier.
